Last reviewed · How we verify
methylcantharidimide tablets
Methylcantharidimide is a cantharidin derivative that induces apoptosis and inhibits protein phosphatase 2A (PP2A), leading to anti-tumor effects.
Methylcantharidimide is a cantharidin derivative that induces apoptosis and inhibits protein phosphatase 2A (PP2A), leading to anti-tumor effects. Used for Various cancers (specific indications not well-documented in Western literature).
At a glance
| Generic name | methylcantharidimide tablets |
|---|---|
| Also known as | GANYU |
| Sponsor | Suzhou Municipal Hospital |
| Drug class | PP2A inhibitor; anti-tumor agent |
| Target | Protein phosphatase 2A (PP2A) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Cantharidin and its derivatives are known to inhibit serine/threonine protein phosphatase 2A (PP2A), which disrupts cellular signaling pathways critical for cancer cell survival and proliferation. By blocking PP2A activity, methylcantharidimide promotes apoptosis in cancer cells and may enhance immune responses. The drug has been used in traditional Chinese medicine and has demonstrated activity in various cancer models.
Approved indications
- Various cancers (specific indications not well-documented in Western literature)
Common side effects
- Gastrointestinal toxicity
- Hematologic effects
- Hepatotoxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- methylcantharidimide tablets CI brief — competitive landscape report
- methylcantharidimide tablets updates RSS · CI watch RSS
- Suzhou Municipal Hospital portfolio CI